KRAS G12C
13 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations (NCT05005234) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-13 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (NCT07083479) | Elicio Therapeutics |
Track KRAS G12C automatically
Every clearance here is in the API, with alerts when new ones post.